Estimating the future burden of cardiovascular disease and the value of lipid and blood pressure control therapies in China

BMC Health Services Research

Volumn 16, Issue 1, 2016, Pages

  Stevens, Warren ^a   Peneva, Desi ^a   Li, Jim Z ^b   Liu, Larry Z ^c   Liu, Gordon ^d   Gao, Runlin ^e   Lakdawalla, Darius N ^f  

^a PRECISION HEALTH ECONOMICS   (United States)

^b PFIZER INC   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d PEKING UNIVERSITY   (China)

^e FUWAI HOSPITAL   (China)

^f UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Blood pressure; Cardiovascular disease; China; Epidemiology; Lipids; Social value

Indexed keywords

LIPID;

ADULT; AGED; BLOOD; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CHINA; COST OF ILLNESS; ECONOMICS; FEMALE; GOVERNMENT; HEALTH CARE COST; HUMAN; HYPERLIPIDEMIAS; HYPERTENSION; MALE; MIDDLE AGED; MORBIDITY; MYOCARDIAL INFARCTION; PHYSIOLOGY; PREVALENCE; RISK FACTOR; STROKE;

ADULT; AGED; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CHINA; COST OF ILLNESS; FEMALE; GOVERNMENT PROGRAMS; HEALTH CARE COSTS; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; LIPIDS; MALE; MIDDLE AGED; MORBIDITY; MYOCARDIAL INFARCTION; PREVALENCE; RISK FACTORS; STROKE;

EID: 84977663213     PISSN: None     EISSN: 14726963     Source Type: Journal    
DOI: 10.1186/s12913-016-1420-8     Document Type: Article

References (53)

1. Yang G, Wang Y, Zeng Y, Gao GF, Liang X, Zhou M, et al. Rapid health transition in China, 1990-2010: findings from the Global Burden of Disease Study 2010. Lancet. 2013;381(9882):1987-2015.
2. Tang S, Ehiri J, Long Q. China's biggest, most neglected health challenge: Non-communicable diseases. Infect Dis Poverty. 2013;2(1):7.
3. Hu SS, Kong LZ, Gao RL, Zhu ML, Wang W, Wang YJ, et al. Outline of the report on cardiovascular disease in China, 2010. Biomed Environ Sci. 2012;25(3):251-6.
4. Yusuf S, Reddy S, Ôunpuu S, Anand S. Global burden of cardiovascular diseases part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation. 2001;104(22):2746-53.
5. Yusuf S, Reddy S, Ôunpuu S, Anand S. Global burden of cardiovascular diseases Part II: Variations in cardiovascular disease by specific ethnic groups and geographic regions and prevention strategies. Circulation. 2001;104(23):2855-64.
6. Jiang G, Wang D, Li W, Pan Y, Zheng W, Zhang H, et al. Coronary heart disease mortality in China: age, gender, and urban-rural gaps during epidemiological transition. Rev Panam Salud Publica. 2012;31(4):317-24.
7. Ford ES, Ajani UA, Croft JB, Critchley JA, Labarthe DR, Kottke TE, et al. Explaining the decrease in U.S. deaths from coronary disease, 1980-2000. N Engl J Med. 2007;356(23):2388-98.
8. Wang D, He Y, Li Y, Luan D, Yang X, Zhai F, et al. Dietary patterns and hypertension among Chinese adults: a nationally representative cross-sectional study. BMC Public Health. 2011;11:925.
9. Fryar CD, Hirsch R, Eberhardt MS, Yoon SS, Wright JD. Hypertension, high serum total cholesterol, and diabetes: Racial and ethnic prevalence differences in U.S. adults, 1999-2006. NCHS data brief, no 36. National Center for Health Statistics, Hyattsville, MD. 2010. http://www.cdc.gov/nchs/data/databriefs/db36.htm. Accessed 23 Sep 2015.
10. State Council of the People's Republic of China. Several Opinions of the State Council on Promoting the Development of the Health Service Industry. 2013. http://www.gov.cn/zwgk/2013-10/14/content-2506399.htm. Accessed 23 Sep 2015.
11. McAlister FA, Lawson FM, Teo KK, Armstrong PW. Randomised trials of secondary prevention programmes in coronary heart disease: systematic review. BMJ. 2001;323(7319):957-62.
12. Clark AM, Hartling L, Vandermeer B, McAlister FA. Meta-analysis: secondary prevention programs for patients with coronary artery disease. Ann Intern Med. 2005;143(9):659-72.
13. Khunti K, Stone M, Paul S, Baines J, Gisborne L, Farooqi A, et al. Disease management programme for secondary prevention of coronary heart disease and heart failure in primary care: a cluster randomised controlled trial. Heart. 2007;93(11):1398-405.
14. Neubeck L, Redfern J, Fernandez R, Briffa T, Bauman A, Freedman SB. Telehealth interventions for the secondary prevention of coronary heart disease: a systematic review. Eur J Cardiovasc Prev Rehabil. 2009;16(3):281-9.
15. Turkstra E, Hawkes AL, Oldenburg B, Scuffham PA. Cost-effectiveness of a coronary heart disease secondary prevention program in patients with myocardial infarction: results from a randomised controlled trial (ProActive Heart). BMC Cardiovasc Disord. 2013;13(1):33.
16. Cole JA, Smith SM, Hart N, Cupples ME. Systematic review of the effect of diet and exercise lifestyle interventions in the secondary prevention of coronary heart disease. Cardiol Res Pract. 2011;2011:232351.
17. Grabowski DC, Lakdawalla DN, Goldman DP, Eber M, Liu LZ, Abdelgawad T, et al. The large social value resulting from use of statins warrants steps to improve adherence and broaden treatment. Health Aff. 2012;31(10):2276-85.
18. Brugts JJ, Yetgin T, Hoeks SE, Gotto AM, Shepherd J, Westendorp RGJ, et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ. 2009;338. doi: 10.1136/bmj.b2376.
19. Cobiac LJ, Magnus A, Barendregt JJ, Carter R, Vos T. Improving the cost-effectiveness of cardiovascular disease prevention in Australia: a modelling study. BMC Public Health. 2012;12:398.
20. Saib A, Sabbah L, Perdrix L, Blanchard D, Danchin N, Puymirat E. Evaluation of the impact of the recent controversy over statins in France: the EVANS study. Arch Cardiovasc Dis. 2013;106(10):511-6.
21. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366(9493):1267-78.
22. Conly J, Clement F, Tonelli M, Hemmelgarn B, Klarenbach S, Lloyd A, et al. Cost-effectiveness of the use of low- and high-potency statins in people at low cardiovascular risk. CMAJ. 2011;183(16):E1180-8.
23. Erickson KF, Japa S, Owens DK, Chertow GM, Garber AM, Goldhaber-Fiebert JD. Cost-effectiveness of statins for primary cardiovascular prevention in chronic kidney disease. J Am Coll Cardiol. 2013;61(12):1250-8.
24. Greving JP, Visseren FL, de Wit GA, Algra A. Statin treatment for primary prevention of vascular disease: whom to treat? Cost-effectiveness analysis. BMJ. 2011;342:d1672.
25. Mitchell AP, Simpson RJ. Statin cost effectiveness in primary prevention: a systematic review of the recent cost-effectiveness literature in the United States. BMC Res Notes. 2012;5:373.
26. Lazar LD, Pletcher MJ, Coxson PG, Bibbins-Domingo K, Goldman L. Cost-effectiveness of statin therapy for primary prevention in a low-cost statin era. Circulation. 2011;124(2):146-53.
27. Yusuf S, Islam S, Chow CK, Rangarajan S, Dagenais G, Diaz R, et al. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey. Lancet. 2011;378(9798):1231-43.
28. Popkin BM, Du S, Zhai F, Zhang B. Cohort Profile: The China Health and Nutrition Survey - monitoring and understanding socio-economic and health change in China, 1989-2011. Int J Epidemiol. 2010;39(6):1435-40.
29. Sussmuth-Dyckerhoff C, Wang, J. China's Health Care Reforms. Health Int. 2010;10:1.
30. United Nations Department of Economic and Social Affairs Population Division - Population Estimates and Projections Section. World Population Prospects: The 2012 Revision. http://esa.un.org/unpd/wpp/index.htm. Accessed 15 Sep 2015.
31. Mendis S, Lindholm LH, Mancia G, Whitworth J, Alderman M, Lim S, et al. World Health Organization (WHO) and International Society of Hypertension (ISH) risk prediction charts: assessment of cardiovascular risk for prevention and control of cardiovascular disease in low and middle-income countries. J Hypertens. 2007;25(8):1578-82.
32. Haltmaier J. Challenges for the future of Chinese economic growth. U.S. Board of Governors of the Federal Reserve System International Finance Discussion Papers. 2013; 1072:1.
33. Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O'Rourke M, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol. 2000;18(10):2095-103.
34. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005;353(2):123-32.
35. Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J, Barnes E, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380(9841):581-90.
36. Ebrahim S, Taylor FC, Brindle P. Statins for the primary prevention of cardiovascular disease. BMS. 2014;348:g280.
37. Law M, Morris J, Wald N. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;338:b1665.
38. Wald DS, Morris JK, Wald NJ. Randomized polypill crossover trial in people aged 50 and over. PLoS One. 2012;7(7):e41297.
39. Zeng W. A price and use comparison of generic versus originator cardiovascular medicines: a hospital study in Chongqing, China. BMC Health Serv Res. 2013;13(1):390.
40. Lewey J, Shrank WH, Bowry AD, Kilabuk E, Brennan TA, Choudhry NK. Gender and racial disparities in adherence to statin therapy: a meta-analysis. Am Heart J. 2013;165(5):665-78. e1.
41. Zeng W, Xi H, Godman B, Finlayson AE, Malmstrom RE. Ongoing initiatives to improve prescribing efficiency in China; statins as a case history. 2014.
42. Wang Z, Wang X, Chen Z, Wang W, Zhu H, Chen W, et al. Hypertension control in community health centers across china: Analysis of antihypertensive drug treatment patterns. Am J Hyperten. 2013;27(2):252-59.
43. Le C, Zhankun S, Jun D, Keying Z. The economic burden of hypertension in rural south-west China. Trop Med Int Health. 2012;17(12):1544-51.
44. Chow GC. China's Economic Transformation. Oxford: Blackwell; 2015.
45. Wei JW, Heeley EL, Jan S, Huang Y, Huang Q, Wang J-G, et al. Variations and determinants of hospital costs for acute stroke in China. PLoS One. 2010;5(9):e13041.
46. Viscusi WK, Aldy JE. The value of a statistical life: a critical review of market estimates throughout the world. J Risk Uncertain. 2003;27(1):5-76.
47. Hammitt JK, Zhou Y. The economic value of air-pollution-related health risks in China: a contingent valuation study. Environ Resour Econ. 2006;33(3):399-423.
48. Wang H, Mullahy J. Willingness to pay for reducing fatal risk by improving air quality: a contingent valuation study in Chongqing, China. Sci Total Environ. 2006;367(1):50-7.
49. Wang H, He J. The value of statistical life: a contingent investigation in China. World Bank Policy Research Working Paper Series, Vol. 2010.
50. Moran A, Gu D, Zhao D, Coxson P, Wang YC, Chen CS, et al. Future cardiovascular disease in China: markov model and risk factor scenario projections from the coronary heart disease policy model-China. Circ Cardiovasc Qual Outcomes. 2010;3(3):243-52.
51. The World Bank. Toward a healthy and harmonious life in China: Stemming the rising tide of non-communicable diseases: Human Development Unit: East Asia and Pacific Region 2011 Contract No.: 62318-CN.
52. Wright JT, Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV, et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373(22):2103-16.
53. Minder CM, Blumenthal RS, Blaha MJ. Statins for primary prevention of cardiovascular disease: the benefits outweigh the risks. Curr Opin Cardiol. 2013;28(5):554-60.